Evoke Pharma (NASDAQ:EVOK) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of EVOK stock opened at $3.68 on Wednesday. The company has a market capitalization of $5.47 million, a price-to-earnings ratio of -0.33 and a beta of 0.12. The company has a 50-day simple moving average of $4.56 and a 200 day simple moving average of $4.72. Evoke Pharma has a 52 week low of $3.44 and a 52 week high of $12.32.

Institutional Trading of Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC increased its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 at the end of the most recent reporting period.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.